OIM
EWTX icon

Oracle Investment Management’s Edgewise Therapeutics EWTX Stock Holding History

Oracle Investment Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$951K Buy
+38,343
New +$770K 0.57% 14

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Oracle Investment Management's EWTX Position: Q4 2025 in Review

Oracle Investment Management opened a new position in Edgewise Therapeutics (EWTX) in Q4 2025: 38,343 shares worth $951K. The stake represents 0.57% of the portfolio and ranks #14 among its holdings.

199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Oracle Investment Management held 38,343 shares of Edgewise Therapeutics worth $951K as of Q4 2025.
  • Edgewise Therapeutics was a new Oracle Investment Management position in Q4 2025.
  • Edgewise Therapeutics made up 0.57% of Oracle Investment Management's portfolio in Q4 2025, its #14 holding.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Oracle Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.